Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Zai Lab Ltd

Get SEC filing alerts via email and in your feed for Zai Lab Ltd

ZLAB

Zai Lab Ltd

About Zai Lab Ltd

Zai Lab Limited is a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies in oncology, immunology, neuroscience, and infectious diseases. It offers a broad pipeline of proprietary and partnered products, with a strong presence in Greater China and the U.S. market. The company leverages strategic collaborations, licensing agreements, and a robust R&D infrastructure to address significant unmet medical needs worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Zai Lab Ltd

1
1
Zai Lab Ltd Zai Lab Reports Q1 2026 Revenue of $99.6 Million, Net Loss of $51.0 Million

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Zai Lab Ltd Zai Lab Reports 15% Revenue Increase to $460.2 Million for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Zai Lab Ltd Zai Lab Reports 13% Revenue Growth to $116.1 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Zai Lab Ltd Zai Lab Reports 9% Revenue Growth and Reduced Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Zai Lab Ltd Zai Lab Reports 22% Revenue Growth to $106.5 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Zai Lab Ltd Zai Lab Reports 48% Revenue Growth, Net Loss Reduction in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments